Volume 28, Issue 4, April 2023

This commentary remarks on the recently published article by Gouda et al on developing mutation-agnostic liquid biopsy, emphasizing the different types of liquid biopsies that are available to detect cancer.

The approval of adagrasib for non–small cell lung cancer is a milestone in drug development. This commentary highlights the history of the research that led to this breakthrough that will help many patients with KRAS-mutated cancers to live longer and better.

Traditional imaging techniques are insufficient to assess the response of lymph nodes (LNs) to neoadjuvant chemotherapy. This article evaluates the effectiveness of a CT-based radiomics model in predicting the axillary pathological complete response after neoadjuvant chemotherapy.

The objective of this study was to determine the landscape of PD-L1 protein expression in breast cancer using the DAKO 22C3 assay and to compare PD-L1–positive and PD-L1–negative cancers by comprehensive genomic profiling to determine if these populations differ in clinical or genomic characteristics.

This article reports an institutional experience with brain metastases from biliary tract cancer and provides clinical and genomic characterizations of these patients.

This article reports on the inhibitory effect of anlotinib in GIST cell lines with different gene mutations, evaluating the efficacy and safety of second-line treatment of GIST with anlotinib compared with second-line treatment with sunitinib in the same period. The clinical trial registration number is NCT04106024.

Based on the results of the JAVELIN Renal 101 trial, avelumab plus axitinib has been approved as first-line treatment for advanced renal cell carcinoma. To provide long-term safety and efficacy data, this article reports 5-year follow-up results from the JAVELIN Renal 100 phase Ib trial.

Despite positive results for other cancers, most antibody-based therapies failed to improve outcomes in patients with advanced renal cell carcinoma (RCC). This review summarizes the evolving landscape of RCC therapeutics and describes recent clinical trials with emerging antibody-based therapeutics, as well as the challenges to be overcome for the successful creation of therapeutic antibodies for treating RCC.

This article reports on the promising benefits of the GOLDEN geriatric hematology-oncology program developed in a tertiary cancer center.

Currently, there is no well-established treatment regimen for patients who cannot tolerate ibrutinib. This article reviews the literature and provides guidance on treating ibrutinib-intolerant patients with B-cell malignancies.

This article evaluates differences in clinicopathological characteristics and outcomes of patients undergoing surgical resection for non-alcoholic fatty liver disease-associated and non-alcoholic steatohepatitis-associated hepatocellular carcinoma compared with other etiologies.

This review provides practical guidance on the management of adverse events related to adagrasib treatment and best practices for patient and caregiver counseling to facilitate optimal outcomes for patients.

This study evaluated hyperprogression risk with the use of immune checkpoint inhibitor (ICI) in the first-, second-, or later-line treatment of advanced non-small cell lung cancer, providing insight into hyperprogression risk with contemporary first-line ICI treatment.

This pilot study examined how patients make the decision of whether or not to undergo adjuvant anti-PD1 immunotherapy when made aware of quantitative risks and benefits. This article examines the factors that influenced patient decisions, satisfaction with their decision prospectively, and health-related quality of life.

Although ERβ is expressed in triple-negative breast cancer (TNBC), its functional role is not well understood. This case report examines the efficacy of the selective estrogen receptor modulator tamoxifen in p53-mutant TNBC with brain metastases.

This review identifies the components of existing mobile health app-based interventions for patients with breast cancer who are undergoing chemotherapy.

Results of a previously reported phase I trial showed that monthly NHS-IL12 had an acceptable safety profile. This trial was expanded to include a biweekly high exposure cohort where patients with advanced cancers received NHS-IL12 every 2 weeks. Results are reported here.

Repeat biopsies are uncommon in metastatic castration–resistant prostate cancer (CRPC), limiting the feasibility of tissue–based biomarkers. This article evaluates the feasibility and utility of blood–based biomarkers to identify platinum–sensitive mCRPC.

Detection of methylation patterns in circulating tumor DNA (ctDNA) can offer a novel approach for cancer diagnostics given the unique signature for each tumor type. This article reports a next-generation sequencing-based assay targeting 32 CpG sites to detect colorectal cancer-specific ctDNA

Since January 2022 in Israel, high-risk populations with underlying health conditions were advised to receive a fourth dose of the BNT162b2 vaccine against SARS-CoV-2. This article reports on vaccine-induced immunity among oncology patients undergoing systemic anti-cancer therapy before and after the 4th-BNT162b2-dose.

With increasing cancer-related healthcare spending, there has been a greater emphasis on payment reforms to incentivize lower costs while maintaining high-quality care in oncology. This article focuses on provider- and practice-level factors associated with oncologist participation and performance in MIPS, the payment system used by the Centers for Medicare and Medicaid Services.